Skip to content

Pneumonia, Mycoplasma

BASICS

  • Definition: Bronchopulmonary infection caused by Mycoplasma species, most commonly Mycoplasma pneumoniae
  • Synonyms: Primary atypical pneumonia, Eaton agent pneumonia, cold agglutinin-positive pneumonia, walking pneumonia
  • Typical population: Children/young adults, but can occur in all ages; epidemics in close communities (dormitories, barracks, skilled nursing facilities)
  • Incubation: 1–4 weeks (average 2–3 weeks)
  • Course: Usually acute; often begins as upper respiratory infection and may progress to pneumonia

EPIDEMIOLOGY

  • US incidence: ~1 million cases/year (annual infection rate 1%)
  • Peak age: 5–20 years (rare <5 years)
  • Season: Autumn/winter
  • Responsible for: Up to 15–20% of all community-acquired pneumonia (CAP) cases yearly
  • Predominant sex: Male = Female
  • Epidemics: Close living quarters (schools, military, nursing homes)

ETIOLOGY AND PATHOPHYSIOLOGY

  • Pathogen: M. pneumoniae (short-rod, no cell wall, not seen on Gram stain)
  • Transmission: Aerosol droplets; highly contagious
  • Pathogenicity: Attaches to respiratory epithelium β†’ ciliary dysfunction β†’ persistent hacking cough
  • Other: May worsen asthma or COPD; can cause extrapulmonary manifestations (neurologic, dermatologic, cardiac)

RISK FACTORS

  • Immunocompromised states (HIV, chemotherapy)
  • Smoking
  • Close communal living
  • Age (school-aged children, young adults)

ASSOCIATED CONDITIONS

  • Asthma exacerbation (children)
  • COPD flare
  • Extrapulmonary: rashes, arthritis, cardiac conduction defects, neurologic symptoms

DIAGNOSIS

History

  • Gradual onset: headache, malaise, low-grade fever, chills
  • Nonproductive cough, often paroxysmal and persistent
  • Pleuritic chest pain, pharyngitis, rhinorrhea, otalgia, sinusitis
  • May progress to pneumonia (5–10% cases)
  • Extrapulmonary: arthralgias, rash, hemolysis, cardiac/neurologic complications
  • Asthma/COPD exacerbation possible

Physical Exam

  • Often unremarkable early
  • Fever, hacking/pertussis-like cough, lassitude
  • Later: rhonchi, rales, wheezes, mild pharyngeal erythema, sometimes pleural friction rub
  • Rare: skin rashes (erythema multiforme, Stevens-Johnson syndrome)

DIFFERENTIAL DIAGNOSIS

  • Viral/bacterial/fungal pneumonia
  • Tuberculosis
  • Other atypical pneumonia: Chlamydia, Legionella, Coxiella, Francisella, Pneumocystis
  • COVID-19 (recommend testing to rule out)

DIAGNOSTIC TESTS & INTERPRETATION

  • Clinical diagnosis is common; treat empirically if suspicious
  • PCR for M. pneumoniae DNA (nasopharyngeal/throat swab, BAL) is most sensitive/specific if needed
  • WBC: normal or elevated; ESR: may be high
  • Procalcitonin: not recommended
  • Cold agglutinins: positive in 50%, but neither sensitive nor specific
  • CXR: reticulonodular or patchy lower lobe infiltrates; 10–15% have small pleural effusions
  • CT: patchy "tree-in-bud" opacities, segmental ground glass
  • Gram stain/culture: Not helpful (organism lacks cell wall, slow growth)

TREATMENT

General Measures

  • Supportive care (fluids, rest, oxygen as needed)
  • Empiric antibiotics to cover likely pathogens
  • Albuterol for wheeze; corticosteroids if extrapulmonary symptoms

Medications

First Line

  • Doxycycline (preferred for CAP in adults and children >8 yrs)
  • Adults: 100 mg PO BID Γ— 14 days
  • Children >8 yrs: 2–4 mg/kg/day (max 200 mg/day) divided BID
  • Azithromycin
  • Adults: 500 mg PO Γ— 1 day, then 250 mg daily Γ— 4 days
  • Children >3 months: 10 mg/kg Γ— 1 day (max 500 mg), then 5 mg/kg (max 250 mg) days 2–5
  • Clarithromycin
  • Adults: 500 mg PO BID Γ— 14–21 days
  • Children >6 months: 15 mg/kg/day divided BID Γ— 10–14 days
  • Erythromycin
  • Adults: 500 mg PO q6h Γ— 14–21 days
  • Children: 20–50 mg/kg/day divided q6–8h Γ— 10–14 days

Second Line (Adults only)

  • Levofloxacin: 750 mg PO/IV daily Γ— 5 days
  • Moxifloxacin: 400 mg PO/IV daily Γ— 7–14 days
  • Gemifloxacin: 320 mg PO daily Γ— 5–7 days

Special Populations

  • Pregnancy: Azithromycin preferred (Category B); avoid doxycycline and fluoroquinolones.
  • Children <8 years: Macrolides preferred.

HOSPITALIZATION/INPATIENT CRITERIA

  • Severe CAP risk class IV/V
  • Elderly or significant comorbidities
  • Inability to maintain oxygen saturation
  • Altered mental status, hemodynamic instability, severe neurologic or extrapulmonary findings

ONGOING CARE

  • Follow-up CXR: In patients >50 years and all smokers (6–8 weeks post-recovery)
  • Monitor for complications: Rash, neurologic symptoms, worsening respiratory status
  • Antibiotic prophylaxis for close contacts: Not routinely recommended

PATIENT EDUCATION

  • Smoking cessation
  • Hand hygiene, droplet/contact precautions
  • Symptoms usually resolve in 2 weeks, but cough may persist longer

PROGNOSIS

  • Usually excellent with appropriate therapy
  • Severe or fatal cases rare (elderly, comorbid, sickle cell)

COMPLICATIONS

  • Most common: Reactive airway disease, hemolytic anemia, erythema multiforme
  • Rare: Meningoencephalitis, GBS, myocarditis, pericarditis, Stevens-Johnson syndrome, acute respiratory distress syndrome, nephritis

ICD-10

  • J15.7 Pneumonia due to Mycoplasma pneumoniae

CLINICAL PEARLS

  • Mycoplasma pneumoniae is a leading cause of atypical ("walking") pneumonia, especially in school-aged children and young adults.
  • Diagnosis is usually clinical; PCR confirms.
  • Responds well to empiric doxycycline or macrolide therapy.
  • Outbreaks in dorms, barracks, nursing homes.
  • May exacerbate asthma/COPD.